Christina Abele

Christina Abele

Auto-generated profile, based on publicly available information

Christina Abele

Psychological Aging Research (PAR), Department of Psychology, Faculty V: School of Life Sciences, University of Siegen, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2024 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Open access
PDF file
KMKatharina Mohr
Katharina Mohr
BKBrent Keeling
Brent Keeling
KKKlaus Kaier
Klaus Kaier
TNThomas Neusius
Thomas Neusius
RRRachel P Rosovsky
Rachel P Rosovsky
ESEric A Secemsky
Eric A Secemsky
Catheter-directed treatment (CDT) of acute pulmonary embolism (PE) is entering a growth phase in Europe following a steady increase in the United States (US) in the past decade, but the potential economic impact on European healthcare systems remains unknown. We built two statistical models for the monthly trend of proportion of CDT among patients with severe (intermediate- or high-risk) PE in the US. The conservative model was based on admission data from the National Inpatient Sample (NIS) 2016-2020, and the model reflecting increasing access to advanced treatment from the PERTTM national quality assurance database registry 2018-2021. By applying these models to the forecast of annual PE-related hospitalizations in Germany, we calculated the annual number of severe PE cases and the expected increase in CDT use for the period 2025-2030. The NIS-based model yielded a slow increase, reaching 3.1% (95% CI 3.0-3.2%) among all hospitalizations with PE in 2030; in the PERT-based model, increase would be steeper, reaching 8.7% (8.3-9.2%). Based on current reimbursement rates, we estimated an increase of annual costs for PE-related hospitalizations in Germany ranging from 15.3 to 49.8 million euros by 2030. This calculation does not account for potential cost savings, including those from reduced length of hospital stay. Our approach and results, which may be adapted to other European healthcare systems, provide a benchmark for healthcare costs expected to result from CDT. Data from ongoing trials on clinical benefits and cost savings are needed to determine cost-effectiveness and inform reimbursement decisions.

14 May 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
LVLuca Valerio
Luca Valerio
Thomas GrochtdreisThomas Grochtdreis
Thomas Grochtdreis
AMAnna C Mavromanoli
Anna C Mavromanoli
IFIoannis Farmakis
Ioannis Farmakis
CAChristina Abele
Christina Abele
SKStavros Konstantinides
Stavros Konstantinides
Aims: It has not been conclusively established whether and to what extent pulmonary embolism (PE) affects health-related quality of life (HrQoL). We aimed to assess the long-term independent association of PE with HrQoL to provide reference values for interventional studies and support quantification of the burden of PE in terms of quality- or disability-adjusted life years (QALYs and DALYs). Methods and results: A total of 1005 patients from a prospective multicenter study, followed 3 and 12 months after PE, were successfully matched to 3058 individuals from the general population of the same country based on age, sex, and key comorbidities. Differences between acute PE survivors and matched controls in the ordinal EQ-5D-5L HrQoL dimensions were assessed using multivariable ordinal regression, in the HrQoL index (reflecting overall HrQoL) using multivariable-adjusted mixed linear regression. Both multiple imputation and complete case analysis were performed. Compared with controls, patients reported worse HrQoL in the dimensions self-care, usual activities, and anxiety/depression, and worse HrQoL index at both 3 [adjusted difference −0.04 (95% CI: −0.06, −0.039) in a range from 0 to 1] and 12 months [−0.02 (95% CI: −0.04, −0.01)] in the imputation analysis. Complete case analysis showed similar results. The annual disability weight of PE for DALY calculation was conservatively estimated at 0.03 (95% CI: 0.02, 0.04). Conclusion: PE was independently associated with a moderate decrease in HrQoL, which persisted 12 months after the acute episode despite partial recovery over time. This degree of impairment is comparable to that imposed by several other cardiopulmonary diseases.

1 July 2024 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
PDF file
KMKatharina Mohr
Katharina Mohr
PMPhilipp Mildenberger
Philipp Mildenberger
TNThomas Neusius
Thomas Neusius
KCKonstantinos C. Christodoulou
Konstantinos C. Christodoulou
IFIoannis Farmakis
Ioannis Farmakis
LVLuca Valerio
Luca Valerio
Aims: Patients surviving acute pulmonary embolism (PE) necessitate long-term treatment and follow-up. We estimated, the chronic economic impact of PE on the German healthcare system. Methods and results: We calculated the direct cost of illness during the first year after discharge for the index PE, analysing data from a multicentre prospective cohort study in Germany. Main and accompanying readmission diagnoses were used to calculate DRG-based hospital reimbursements; anticoagulation costs were estimated from the exact treatment duration and each drug's unique national identifier; and outpatient post-PE care costs from guidelines-recommended algorithms and national reimbursement catalogues. Of 1017 patients enrolled at 17 centres, 958 (94%) completed ≥3-month follow-up; of those, 24% were rehospitalized (0.34 [95% CI 0.30–0.39] readmissions per PE survivor). Age, coronary artery, pulmonary and kidney disease, diabetes, and (in the sensitivity analysis of 837 patients with complete 12-month follow-up) cancer, but not recurrent PE, were independent cost predictors by hurdle gamma regression accounting for zero readmissions. The estimated rehospitalization cost was €1138 (95% CI 896–1420) per patient. Anticoagulation duration was 329 (IQR 142–365) days, with estimated average per-patient costs of €1050 (median 972; IQR 458–1197); costs of scheduled ambulatory follow-up visits amounted to €181. Total estimated direct per-patient costs during the first year after PE ranged from €2369 (primary analysis) to €2542 (sensitivity analysis). Conclusion: By estimating per-patient costs and identifying cost drivers of post-PE care, our study may inform decisions concerning implementation and reimbursement of follow-up programmes aiming at improved cardiovascular prevention.

6 February 2026 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
LVLuca Valerio
Luca Valerio
KCKonstantinos C. Christodoulou
Konstantinos C. Christodoulou
CAChristina Abele
Christina Abele
VCVincent Ten Cate
Vincent Ten Cate
Karsten KellerKarsten Keller
Karsten Keller
SBStefano Barco
Stefano Barco
Post-thrombotic syndrome (PTS) is a common complication of deep vein thrombosis (DVT) of the lower extremities, associated with reduced quality of life and high healthcare costs. No reliable estimates exist of PTS risk by DVT location and its burden in the general population. To estimate: (1) the risk of PTS by anatomical location of DVT; (2) the age- and sex-specific incidence and prevalence of PTS in Europe. We performed a systematic review and mixed-effects meta-analysis of studies reporting the cumulative incidence of PTS defined by Villalta score in patients with iliofemoral, femoropopliteal, and distal DVT. We then applied location-specific risk estimates to age- and sex-specific European DVT incidence data using a life table approach with Monte Carlo simulations to calculate the annual incidence and prevalence of PTS. Among 49 studies (N=14 171, 15 interventional, 34 observational), estimated PTS risk was 51.1% (95%CI: 39.5-62.7%) for iliofemoral, 30.7% (21.4-39.9%) for femoropopliteal, and 22.8% (17.1-29.8%) for distal DVT, assuming no systematic use of compression stockings for proximal DVT. We estimate 250 000 (95%CI: 220 000-315 000) new PTS cases annually in Europe (incidence 0.34 [0.29-0.42] per 1 000), and 4.86 million (4.11-5.88) prevalent cases (prevalence 6.5 [5.5-7.9] per 1 000). PTS risk increases with proximal DVT extent. Approximately 5 million individuals in Europe are estimated to live with PTS, underscoring the need for targeted prevention and treatment strategies.

18 November 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
KCKonstantinos C. Christodoulou
Konstantinos C. Christodoulou
SBStefano Barco
Stefano Barco
CAChristina Abele
Christina Abele
CLCorrado Lodigiani
Corrado Lodigiani
MMManuel Monreal
Manuel Monreal
LVLuca Valerio
Luca Valerio
Background: The burden of atherosclerosis may have prognostic implications for patients affected by venous thromboembolism (VTE). We aimed to assess the association of the presence and extent of atherosclerotic disease with long‐term clinical outcomes in patients with acute pulmonary embolism (PE). Methods: In patients with PE from the Hokusai‐VTE trial, we assessed the association between the presence of atherosclerotic disease in multiple (polyvascular disease), one, or no vascular territories (coronary, cerebral, and/or peripheral arteries) and 1‐year risk of VTE or PE recurrence, major bleeding, and all‐cause death. We used univariable and multivariable Cox regression analysis, with adjustment for relevant comorbidities and anticoagulation modeled as a time‐varying covariate. Results: Of 2800 patients, 67 (2.4%) had polyvascular and 357 (12.7%) had single vascular atherosclerotic disease. During 12‐month follow‐up, recurrent VTE was reported for a total of 356 patients, including 208 PE events. A total of 52 patients had a major bleeding event and 91 deaths were recorded. Polyvascular atherosclerotic disease was strongly associated with VTE (adjusted hazard ratio,1.91 [95% CI, 1.05–3.49]) and PE recurrence (adjusted hazard ratio, 2.06 [95% CI, 1.03–4.16]). Polyvascular and single vascular disease were associated with major bleeding and all‐cause death in univariable analysis; however, these associations attenuated after adjustment. Conclusions: The pre‐existing burden of atherosclerosis may have prognostic value with respect to secondary prevention in patients who experienced an acute PE. Optimization of overall cardiovascular risk may be considered by management studies in the follow‐up of this patient population. Registration: URL: www.clinicaltrials.gov ; Unique identifier: identifier: NCT00986154

1 March 2025 in GeroPsych
Verified
Journal Article
Open access
LRLena Rupp
Lena Rupp
CAChristina Abele
Christina Abele
JHJulia Haberstroh
Julia Haberstroh
Dementia grief can be challenging to detect because it is often disenfranchised. This study examined whether mental health professionals detect or overlook dementia grief. An online survey presented health professionals with a case vignette regarding the caregivers of people with dementia (PwD). Based on random assignment, the participants read a case description of a PwD who was deceased or still alive. We analyzed the responses of 381 participants. Significant group differences for the variables grief attribution, loss attribution, expected self-disenfranchisement, grief support/grief group recommendation, and psychotherapeutic/psychiatric counsel recommendation resulted. Even though professionals in this sample had continued grief education, loss and grief attribution in nondeath event losses were significantly lower, confirming that dementia providers disenfranchise dementia grief.